Richard Rosengard
Psychiatry · Phoenix, AZNPI 1861499907
Payments from drug & device makers
Across 162 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$632
- Takeda Pharmaceuticals U.S.A., Inc.$412
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$218
- Almatica Pharma LLC$189
- Lundbeck LLC$180
- Otsuka America Pharmaceutical, Inc.$166
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,72997%
- Education$803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $632 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $412 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $218 |
| Almatica Pharma LLC | 8 | $189 |
| Lundbeck LLC | 9 | $180 |
| Otsuka America Pharmaceutical, Inc. | 6 | $166 |
| Corium, LLC | 8 | $149 |
| Alkermes, Inc. | 7 | $136 |
| Eisai Inc. | 7 | $133 |
| Johnson & Johnson | 4 | $87 |
| Vanda Pharmaceuticals Inc. | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 5 | $71 |
| Neurocrine Biosciences, Inc. | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Bausch Health US, LLC | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Noven Therapeutics, LLC | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,809 in reported general payments places this provider in the 80th percentile of 573 psychiatry providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $18,144 |
| Buspirone Hcl | 213 | $4,467 |
| Clonazepam | 245 | $3,511 |
| Gabapentin | 103 | $2,829 |
| Venlafaxine Hcl | 55 | $2,677 |
| Aripiprazole | 76 | $2,550 |
| Bupropion Hcl SrBupropion Hcl | 79 | $2,451 |
| Ziprasidone Hcl | 19 | $2,069 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $1,906 |
| Duloxetine Hcl | 64 | $1,578 |
| Trazodone Hcl | 150 | $1,325 |
| Nortriptyline Hcl | 31 | $1,225 |
| Methylphenidate Hcl | 31 | $1,224 |
| Alprazolam | 190 | $1,201 |
| Fluoxetine Hcl | 85 | $1,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $632 | $18,14411 claims |
| Almatica Pharma LLCSertraline Hcl | $189 | $1,050106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Phoenix
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Ahmed ElmaadawiPhoenix$395K
- Lee KelleyPhoenix$340K
- Eric ReimanPhoenix$160K
- John PraterPhoenix$101K
- Pallavi JoshiPhoenix$62K
- Padma AkingPhoenix$44K
- Amnon KahanePhoenix$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.